MyFinsight
Home
Blog
About
GuardantHealthMasterLogo_ND_RGBcropped-svg
Guardant Health, Inc. (GH)
GuardantHealthMasterLogo_ND_RGBcropped-svg
Guardant Health, Inc. (GH)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$66,298K
Free Cash flow
-$69,537K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from marketable securit...
Stock-based compensation
Accounts payable and accrued lia...
Others
Negative Cash Flow Breakdown
Sales and marketing expense
Cost of revenue
Research and development expense
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
334,978
301,665
281,266
265,196
Cost of revenue
111,854
101,560
95,842
90,872
Research and development expense
80,508
76,589
85,944
75,790
Sales and marketing expense
172,360
154,430
130,536
115,924
General and administrative expense
35,442
37,037
43,519
37,136
Other segment items
54,956
44,124
53,919
38,199
Net loss
-120,142
-112,075
-128,494
-92,725
Depreciation and amortization
9,561
9,442
10,050
9,408
Operating lease costs
8,587
8,561
8,564
8,571
Gain on extinguishment of convertible notes
0
0
0
0
Stock-based compensation
57,725
47,608
43,190
42,808
Amortization of discount on marketable securities
994
6,986
5,877
-
Unrealized and realized losses (gains) on marketable equity securities
-
-
0
0
Impairment of non-marketable equity securities
0
0
13,582
0
Interest income received on marketable securities
1,238
11,825
0
0
Other
-508
727
-321
335
Accounts receivable, net
6,886
-942
22,204
-14,454
Inventory, net
21,612
-2,025
-4,614
6,428
Prepaid expenses and other current assets, net
16,957
7,238
-2,253
1,331
Other assets, net
-899
-1,063
567
306
Accounts payable and accrued liabilities
44,288
-8,229
53,745
3,277
Other legal liabilities
-
-
0
-
Operating lease liabilities
-9,263
-8,604
-9,502
-9,196
Deferred revenue
-4,730
-3,230
3,952
-3,610
Net cash used in operating activities
-57,778
-65,623
-26,373
-35,413
Purchases of marketable securities
0
249,936
818,231
0
Maturities of marketable debt securities
-
-
0
0
Sales of marketable equity securities
-
-
-
0
Sales of marketable equity securities and other related assets
-
-
0
-
Proceeds from marketable securities
113,232
954,934
-
-
Purchases of non-marketable equity securities
0
-
0
4,000
Purchases of property and equipment
11,759
5,580
27,848
10,350
Acquisition of business, net of cash acquired
-
-
58,988
-
Net cash provided by investing activities
101,473
699,418
-905,067
-14,350
Proceeds from issuance of common stock upon exercise of stock options
17,926
3,651
13,177
3,721
Proceeds from issuances of common stock under employee stock purchase plan
10,362
-
5,905
0
Employee taxes paid related to net share settlement of restricted stock units
8,319
20,650
5,352
2,265
Repurchase of treasury stock
0
0
0
0
Proceeds from reissuance of treasury stock
-
-
87,872
-
Proceeds from equity offerings
-
-
257,128
-
Payment of equity offering costs
-
-
17,668
-
Proceeds from borrowings on convertible senior notes
-
-
402,500
-
Payment of debt issuance costs
0
102
12,299
0
Proceeds from unwinding of convertible note hedges
0
0
0
0
Other
3,045
-4,476
765
2,875
Net cash provided by (used in) financing activities
23,014
-21,577
732,028
4,331
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash
-411
-194
-686
-533
Net increase in cash, cash equivalents and restricted cash
66,298
612,024
-200,098
-45,965
Cash, cash equivalents and restricted cashbeginning of period
1,101,441
489,417
689,515
629,755
Cash, cash equivalents and restricted cashend of period
1,167,739
1,101,441
489,417
689,515
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from marketable
securities
$113,232K
Proceeds from issuance of
common stock upon...
$17,926K
(1051.32%↑ Y/Y)
Proceeds from issuances
of common stock...
$10,362K
(34.92%↑ Y/Y)
Other
$3,045K
(7526.83%↑ Y/Y)
Net cash provided by
investing activities
$101,473K
(1052.89%↑ Y/Y)
Net cash provided by
(used in) financing...
$23,014K
(1317.12%↑ Y/Y)
Canceled cashflow
$11,759K
Canceled cashflow
$8,319K
Net increase in
cash, cash...
$66,298K
(196.97%↑ Y/Y)
Canceled cashflow
$58,189K
Purchases of property and
equipment
$11,759K
(108.16%↑ Y/Y)
Stock-based compensation
$57,725K
(35.95%↑ Y/Y)
Accounts payable and
accrued liabilities
$44,288K
(1718.71%↑ Y/Y)
Depreciation and
amortization
$9,561K
(-4.79%↓ Y/Y)
Operating lease costs
$8,587K
(0.17%↑ Y/Y)
Interest income received
on marketable...
$1,238K
Other assets, net
-$899K
(-131.70%↓ Y/Y)
Other
-$508K
(-141.64%↓ Y/Y)
Employee taxes paid
related to net share...
$8,319K
(12.10%↑ Y/Y)
Net cash used in
operating activities
-$57,778K
(4.16%↑ Y/Y)
Net effect of
foreign exchange rate...
-$411K
(-143.86%↓ Y/Y)
Canceled cashflow
$122,806K
Revenue
$334,978K
(44.33%↑ Y/Y)
Net loss
-$120,142K
(-20.26%↓ Y/Y)
Canceled cashflow
$334,978K
Inventory, net
$21,612K
(217.59%↑ Y/Y)
Prepaid expenses and
other current assets,...
$16,957K
(303.35%↑ Y/Y)
Operating lease
liabilities
-$9,263K
(-0.02%↓ Y/Y)
Accounts receivable, net
$6,886K
(-51.88%↓ Y/Y)
Deferred revenue
-$4,730K
(-128.35%↓ Y/Y)
Amortization of discount on
marketable securities
$994K
Sales and marketing
expense
$172,360K
(59.84%↑ Y/Y)
Cost of revenue
$111,854K
(42.86%↑ Y/Y)
Research and development
expense
$80,508K
(10.97%↑ Y/Y)
Other segment items
$54,956K
(43.19%↑ Y/Y)
General and
administrative expense
$35,442K
(1.46%↑ Y/Y)
Buy us a coffee